A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

NCT00364546 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

877

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis
Pain Intensity Assessment
Arthralgia
Sciatica
Low Back Pain

Interventions

DRUG: CG 5503;tapentadol

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]